Immunologic Research

, Volume 62, Issue 3, pp 386–398 | Cite as

T regulatory cells: Achilles’ heel of Mycobacterium tuberculosis infection?

Interpretive synthesis review article
First Online:

Abstract

T regulatory cells (Treg) constitute a specialized subset of T cells that play a pivotal role in preventing the occurrence of autoimmune diseases by suppressing deleterious activities of immune cells. Contrarily, they can have adverse effect on immune response against infectious diseases where Treg weaken the host immunity leading to enhanced microbial load and thereby increase in severity of the disease. Here, we have attempted to review plethora of information documenting prevalence of Treg in tuberculosis (TB) and their involvement in progression and immunopathogenesis of the disease. Further, we have laid emphasis on the possible use of Treg as a biomarker for determining the TB treatment efficacy. Also, we have discussed the probable contribution of Treg in dampening the efficacy of BCG, the anti-TB vaccine. Finally, we have speculated some of the possible strategies which might be explored by exploiting Treg for enhancing the efficacy of TB management.

Keywords

Tuberculosis Treg Immunology Biomarker Treatment 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Thanks to Department of Science and Technology, Government of India, for providing Inspire fellowship to Ms. Sonali Agrawal. Thanks to NJIL & OMD, Agra, for routine facilities. Thanks to Infolep, The Netherlands, for providing scientific literature.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    World Health Organization (WHO). Global tuberculosis report 2014. Geneva: WHO/HTM/TB/2014.08. 2014. http://www.who.int/tb/publications/global_report/en/.
  2. 2.
    Dooley SW, Jarvis WR, Martone WJ, Snider DE Jr. Multidrug-resistant tuberculosis. Ann Intern Med. 1992;117(3):257–9. doi: 10.7326/0003-4819-117-3-257.PubMedCrossRefGoogle Scholar
  3. 3.
    Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep. 1992;107(6):616–25.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistance tuberculosis. Emerg Infect Dis. 2007;13(3):380–7. doi: 10.3201/eid1303.061400.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Koenig R. Drug resistant tuberculosis in South Africa, XDR TB and HIV prove a deadly combination. Science. 2008;319(5865):894–7. doi: 10.1126/science.319.5865.894.PubMedCrossRefGoogle Scholar
  6. 6.
    Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology. 2010;15(3):433–50. doi: 10.1111/j.1440-1843.2010.01739.x.PubMedCrossRefGoogle Scholar
  7. 7.
    van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002;15(2):294–309. doi: 10.1128/CMR.15.2.294-309.2002.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Abel B, Thieblemont N, Quesniaux VJ, Brown N, Mpagi J, Miyake K, et al. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol. 2002;169(6):3155–62. doi: 10.4049/jimmunol.169.6.3155.PubMedCrossRefGoogle Scholar
  9. 9.
    Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun. 2004;72(4):2400–4. doi: 10.1128/IAI.72.4.2400-2404.2004.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med. 2005;202(12):1715–24. doi: 10.1084/jem.20051782.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Ferwerda G, Girardin SE, Kullberg BJ, Le Bourhis L, de Jong DJ, Langenberg DM, et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 2005;1(3):279–85. doi: 10.1371/journal.ppat.0010034.PubMedCrossRefGoogle Scholar
  12. 12.
    Gandotra S, Jang S, Murray PJ, Salgame P, Ehrt S. Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis. Infect Immun. 2007;75(11):5127–34. doi: 10.1128/IAI.00458-07.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Morikawa F, Nakano A, Nakano H, Oseko F, Morikawa S. Enhanced natural killer cell activity in patients with pulmonary tuberculosis. Jpn J Med. 1989;28(3):316–22. doi: 10.2169/internalmedicine1962.28.316.PubMedCrossRefGoogle Scholar
  14. 14.
    Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol. 1990;144(7):2771–80.PubMedGoogle Scholar
  15. 15.
    Schaible UE, Collins HL, Kaufmann SH. Confrontation between intracellular bacteria and the immune system. Adv Immunol. 1999;71:267–377.PubMedGoogle Scholar
  16. 16.
    Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249–54. doi: 10.1084/jem.178.6.2249.PubMedCrossRefGoogle Scholar
  17. 17.
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61. doi: 10.1126/science.1079490.PubMedCrossRefGoogle Scholar
  18. 18.
    Berod L, Puttur F, Huehn J, Sparwasser T. Tregs in infection and vaccinology: heroes or traitors? Microb Biotechnol. 2012;5(2):260–9. doi: 10.1111/j.1751-7915.2011.00299.x.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167(3):1245–53. doi: 10.4049/jimmunol.167.3.1245.PubMedCrossRefGoogle Scholar
  20. 20.
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–6. doi: 10.1038/ni904.PubMedCrossRefGoogle Scholar
  21. 21.
    Corthay A. How do regulatory T cells work? Scand J Immunol. 2009;70(4):326–36. doi: 10.1111/j.1365-3083.2009.02308.x.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med. 2006;203(7):1701–11. doi: 10.1084/jem.20060772.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225–32. doi: 10.1182/blood-2006-12-064527.PubMedCrossRefGoogle Scholar
  24. 24.
    Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O’Farrelly C, et al. CD39 + FoxP3 + Regulatory T cells suppress pathogenic Th17 cells and are impaired in Multiple Sclerosis. J Immunol. 2009;183:7602–10. doi: 10.4049/jimmunol.0901881.PubMedCrossRefGoogle Scholar
  25. 25.
    Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA. CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8+CD39+ regulatory T cells. Eur J Immunol. 2013;43(7):1925–32. doi: 10.1002/eji.201243286.PubMedCrossRefGoogle Scholar
  26. 26.
    Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171(12):6323–7. doi: 10.4049/jimmunol.171.12.6323.PubMedCrossRefGoogle Scholar
  27. 27.
    Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med. 2006;173(7):803–10. doi: 10.1164/rccm.200508-1294OC.PubMedCrossRefGoogle Scholar
  28. 28.
    Pang H, Yu Q, Guo B, Jiang Y, Wan L, Li J, et al. Frequency of regulatory T-cells in the peripheral blood of patients with pulmonary tuberculosis from shanxi province, china. PLoS ONE. 2013;8(6):e65496. doi: 10.1371/journal.pone.0065496.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, Shanley C, et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol. 2007;179(1):522–31. doi: 10.4049/jimmunol.179.1.522.PubMedCrossRefGoogle Scholar
  30. 30.
    Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, Rudensky AY, et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med. 2007;204(9):2159–69. doi: 10.1084/jem.20062105.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, et al. Characterization of regulatory T cells identified as CD4+CD25highCD39+ in patients with active tuberculosis. Clin Exp Immunol. 2009;156(3):463–70. doi: 10.1111/j.1365-2249.2009.03908.x.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Feruglio SL, Tonby K, Kvale D, Dyrhol-Riise AM. Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection. Clin Exp Immunol. 2015;179(3):454–65. doi: 10.1111/cei.12468.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    He XY, Xiao L, Chen HB, Hao J, Li J, Wang YJ, et al. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis. 2010;29(6):643–50. doi: 10.1007/s10096-010-0908-0.PubMedCrossRefGoogle Scholar
  34. 34.
    Jarvis LB, Matyszak MK, Duggleby RC, Goodall JC, Hall FC, Gaston JS. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol. 2005;35(10):2896–908. doi: 10.1002/eji.200526162.PubMedCrossRefGoogle Scholar
  35. 35.
    Pinheiro MB, Antonelli LR, Sathler-Avelar R, Vitelli-Avelar DM, Spindola-de-Miranda S, Guimarães TM, et al. CD4−CD8− αβ and γδ T cells display inflammatory and regulatory potentials during human tuberculosis. PLoS ONE. 2012;7(12):e50923. doi: 10.1371/journal.pone.0050923.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105–11. doi: 10.1093/intimm/dxp095.PubMedCrossRefGoogle Scholar
  37. 37.
    Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–3. doi: 10.1126/science.1202947.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008;14(5):528–35. doi: 10.1038/nm1749.PubMedCrossRefGoogle Scholar
  39. 39.
    Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7(10):817–23. doi: 10.1038/nri2163.PubMedCrossRefGoogle Scholar
  40. 40.
    Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–61. doi: 10.4049/jimmunol.176.11.6752.PubMedCrossRefGoogle Scholar
  41. 41.
    Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+FoxP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–62. doi: 10.1038/ni1536.PubMedCrossRefGoogle Scholar
  42. 42.
    Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916–26. doi: 10.4049/jimmunol.180.9.5916.PubMedCrossRefGoogle Scholar
  44. 44.
    Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190(7):995–1004. doi: 10.1084/jem.190.7.995.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlowCD4+ T cells. J Exp Med. 1996;183(6):2669–74. doi: 10.1084/jem.183.6.2669.PubMedCrossRefGoogle Scholar
  46. 46.
    Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–9. doi: 10.1038/nature06306.PubMedCrossRefGoogle Scholar
  47. 47.
    Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity. 2014;41(1):89–103. doi: 10.1016/j.immuni.2014.05.019.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21(4):589–601.PubMedCrossRefGoogle Scholar
  49. 49.
    Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. J Exp Med. 1994;180(4):1499–509. doi: 10.1084/jem.180.4.1499.PubMedCrossRefGoogle Scholar
  50. 50.
    Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophages apoptosis. Infect Immun. 1997;65(1):298–304.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Placido R, Mancino G, Amendola A, Mariani F, Vendetti S, Piacentini M, et al. Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. J Pathol. 1997;181(1):31–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Reece ST, Kaufmann SH. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol. 2012;15(1):63–70. doi: 10.1016/j.mib.2011.10.006.PubMedCrossRefGoogle Scholar
  53. 53.
    Rahman S, Gudetta B, Fink J, Granath A, Ashenafi S, Aseffa A, et al. Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions. Am J Pathol. 2009;174(6):2211–24. doi: 10.2353/ajpath.2009.080941.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Green AM, Mattila JT, Bigbee CL, Bongers KS, Lin PL, Flynn JL. CD4+ regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis. 2010;202(4):533–41. doi: 10.1086/654896.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Welsh KJ, Risin SA, Actor JK, Hunter RL. Immunopathology of postprimary tuberculosis: increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clin Dev Immunol. 2011;2011:307631. doi: 10.1155/2011/307631.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991;146(10):3444–51.PubMedGoogle Scholar
  57. 57.
    Himmel ME, Crome SQ, Ivison S, Piccirillo C, Steiner TS, Levings MK. Human CD4+FOXP3+ regulatory T cells produce CXCL8 and recruit neutrophils. Eur J Immunol. 2011;41(2):306–12. doi: 10.1002/eji.201040459.PubMedCrossRefGoogle Scholar
  58. 58.
    Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med. 2008;205(1):105–15. doi: 10.1084/jem.20071367.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D. LAG3 expression in active Mycobacterium tuberculosis infections. Am J Pathol. 2014. doi: 10.1016/j.ajpath.2014.11.003.
  60. 60.
    Periasamy S, Dhiman R, Barnes PF, Paidipally P, Tvinnereim A, Bandaru A, et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. J Infect Dis. 2011;203(9):1256–63. doi: 10.1093/infdis/jir011.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci USA. 2008;105(27):9331–6. doi: 10.1073/pnas.0710441105.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J. Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. J Infect Dis. 2012;205(4):694–6. doi: 10.1093/infdis/jir820.PubMedCrossRefGoogle Scholar
  63. 63.
    Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711. doi: 10.1146/annurev.immunol.21.120601.141040.PubMedCrossRefGoogle Scholar
  64. 64.
    Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–65. doi: 10.1016/B978-0-12-380995-7.00004-5.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008;105(29):10113–8. doi: 10.1073/pnas.0711106105.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87. doi: 10.1016/j.cell.2008.05.009.PubMedCrossRefGoogle Scholar
  67. 67.
    Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10(6):595–602. doi: 10.1038/ni.1731.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Lee JH, Kang SG, Kim CH. FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J Immunol. 2007;178(1):301–11. doi: 10.4049/jimmunol.178.1.301.PubMedCrossRefGoogle Scholar
  69. 69.
    Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB. CD4+CD25+ regulatory T lymphocytes in tuberculous pleural effusion. Chin Med J (Engl). 2008;121(7):581–6.Google Scholar
  70. 70.
    Sharma PK, Saha PK, Singh A, Sharma SK, Ghosh B, Mitra DK. FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med. 2009;179(11):1061–70. doi: 10.1164/rccm.200804-529OC.PubMedCrossRefGoogle Scholar
  71. 71.
    Kursar M, Koch M, Mittrücker HW, Nouailles G, Bonhagen K, Kamradt T, et al. Cutting Edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol. 2007;178(5):2661–5. doi: 10.4049/jimmunol.178.5.2661.PubMedCrossRefGoogle Scholar
  72. 72.
    Quinn KM, McHugh RS, Rich FJ, Goldsack LM, de Lisle GW, Buddle BM, et al. Inactivation of CD4+CD25+ regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol Cell Biol. 2006;84(5):467–74. doi: 10.1111/j.1440-1711.2006.01460.x.PubMedCrossRefGoogle Scholar
  73. 73.
    Ozeki Y, Sugawara I, Udagawa T, Aoki T, Osada-Oka M, Tateishi Y, et al. Transient role of CD4+CD25+ regulatory T cells in mycobacterial infection in mice. Int Immunol. 2010;22(3):179–89. doi: 10.1093/intimm/dxp126.PubMedCrossRefGoogle Scholar
  74. 74.
    Balandina A, Lécart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105(2):735–41. doi: 10.1182/blood-2003-11-3900.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med. 2004;200(3):277–85. doi: 10.1084/jem.20040165.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Möttönen M, Heikkinen J, Mustonen L, Isomäki P, Luukkainen R, Lassila O. CD4+CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 2005;140(2):360–7. doi: 10.1111/j.1365-2249.2005.02754.x.PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41(4):771–8. doi: 10.1002/hep.20649.PubMedCrossRefGoogle Scholar
  78. 78.
    Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004;40(5):1062–71. doi: 10.1002/hep.20454.PubMedCrossRefGoogle Scholar
  79. 79.
    Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004;104(10):3249–56. doi: 10.1182/blood-2004-01-0365.PubMedCrossRefGoogle Scholar
  80. 80.
    Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol. 2004;113(4):756–63. doi: 10.1016/j.jaci.2004.01.772.PubMedCrossRefGoogle Scholar
  81. 81.
    Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol. 2005;35(4):1155–63. doi: 10.1002/eji.200425093.PubMedCrossRefGoogle Scholar
  82. 82.
    Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, Locht C, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med. 2007;176(4):409–16. doi: 10.1164/rccm.200701-084OC.PubMedCrossRefGoogle Scholar
  83. 83.
    Semple PL, Binder AB, Davids M, Maredza A, van Zyl-Smit RN, Dheda K. Regulatory T cells attenuate mycobacterial stasis in alveolar and blood-derived macrophages from patients with tuberculosis. Am J Respir Crit Care Med. 2013;187(11):1249–58. doi: 10.1164/rccm.201210-1934OC.PubMedCrossRefGoogle Scholar
  84. 84.
    Geffner L, Basile JI, Yokobori N, Sabio Y García C, Musella R, Castagnino J, et al. CD4(+) CD25(high) forkhead box protein 3(+) regulatory T lymphocytes suppress interferon-γ and CD107 expression in CD4+ and CD8+ T cells from tuberculous pleural effusions. Clin Exp Immunol. 2014;175(2):235–45. doi: 10.1111/cei.12227.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Wu YE, Peng WG, Cai YM, Zheng GZ, Zheng GL, Lin JH, et al. Decrease in CD4+CD25+FoxP3+ Treg cells after pulmonary resection in the treatment of cavity multidrug-resistant tuberculosis. Int J Infect Dis. 2010;14(9):e815–22. doi: 10.1016/j.ijid.2010.04.005.PubMedCrossRefGoogle Scholar
  86. 86.
    Wergeland I, Assmus J, Dyrhol-Riise AM. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand J Immunol. 2011;73(3):234–42. doi: 10.1111/j.1365-3083.2010.02496.x.PubMedCrossRefGoogle Scholar
  87. 87.
    Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol. 2004;4(11):841–55. doi: 10.1038/nri1485.PubMedCrossRefGoogle Scholar
  88. 88.
    Singh A, Dey AB, Mohan A, Sharma PK, Mitra DK. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells. PLoS ONE. 2012;7(9):e44728. doi: 10.1371/journal.pone.0044728.PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.
    Jackson-Sillah D, Cliff JM, Mensah GI, Dickson E, Sowah S, Tetteh JK, et al. Recombinant ESAT-6-CFP10 fusion protein induction of Th1/Th2 cytokines and FoxP3 expressing Treg cells in pulmonary TB. PLoS ONE. 2013;8(6):e68121. doi: 10.1371/journal.pone.0068121.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, Boom WH, et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol. 2006;144(1):25–34. doi: 10.1111/j.1365-2249.2006.03027.x.PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Arram EO, Hassan R, Saleh M. Increased frequency of CD4+CD25+FoxP3+ circulating regulatory T cells (Treg) in tuberculous patients. Egypt J Chest Dis Tuberc. 2014;63:167–72. doi: 10.1016/j.ejcdt.2013.10.013.CrossRefGoogle Scholar
  92. 92.
    Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette–Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1Pt1):29–35.PubMedGoogle Scholar
  93. 93.
    Parkash O. How to avoid the impact of environmental mycobacteria towards the efficacy of BCG vaccination against tuberculosis? Int J Mycobacteriol. 2014;3:1–4. doi: 10.1016/j.ijmyco.2014.01.006.CrossRefGoogle Scholar
  94. 94.
    Jaron B, Maranghi E, Leclerc C, Majlessi L. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE. 2008;3(7):e2833. doi: 10.1371/journal.pone.0002833.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Luo Y, Jiang W, Da Z, Wang B, Hu L, Zhang Y, et al. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Scand J Immunol. 2012;75(3):293–300. doi: 10.1111/j.1365-3083.2011.02666.x.PubMedCrossRefGoogle Scholar
  96. 96.
    Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7. doi: 10.1038/nature01152.PubMedCrossRefGoogle Scholar
  97. 97.
    Berod L, Stüve P, Varela F, Behrends J, Swallow M, Kruse F, et al. Rapid rebound of the Treg compartment in DEREG mice limits the impact of Treg depletion on mycobacterial burden, but prevents autoimmunity. PLoS ONE. 2014;9(7):e102804. doi: 10.1371/journal.pone.0102804.PubMedCentralPubMedCrossRefGoogle Scholar
  98. 98.
    Chen CY, Huang D, Yao S, Halliday L, Zeng G, Wang RC, et al. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol. 2012;188(9):4278–88. doi: 10.4049/jimmunol.1101291.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Bhattacharya D, Dwivedi VP, Kumar S, Reddy MC, Van Kaer L, Moodley P, et al. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem. 2014;289(48):33404–11. doi: 10.1074/jbc.M114.600452.PubMedCentralPubMedCrossRefGoogle Scholar
  100. 100.
    Zhang HH, Fei R, Xie XW, Wang L, Luo H, Wang XY, et al. Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients. Beijing Da Xue Xue Bao. 2009;41(3):313–8.PubMedGoogle Scholar
  101. 101.
    Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013;132(4):967–77. doi: 10.1002/ijc.27710.PubMedCrossRefGoogle Scholar
  102. 102.
    Shafiani S, Dinh C, Ertelt JM, Moguche AO, Siddiqui I, Smigiel KS, et al. Pathogen-specific Treg cells expand early during Mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12. Immunity. 2013;38(6):1261–70. doi: 10.1016/j.immuni.2013.06.003.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of ImmunologyNational JALMA Institute for Leprosy and Other Mycobacterial DiseasesTajGanj, AgraIndia
  2. 2.Department of BiochemistryNational JALMA Institute for Leprosy and Other Mycobacterial DiseasesTajGanj, AgraIndia

Personalised recommendations